{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:28:24Z","timestamp":1752283704950,"version":"3.41.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:p>We present the case of an 80-year-old man with multitreatment-resistant immunotherapy-induced bullous pemphigoid (BP) who experienced resolution following treatment with biweekly double-dosed (600\u2005mg subcutaneous) dupilumab, an emerging treatment option for BP. Our findings suggest the potential efficacy of intensified dupilumab dosing in managing immunotherapy-induced BP that is multi-treatment resistant or resistant to standard dupilumab dosing.<\/jats:p>","DOI":"10.1093\/ced\/llaf002","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T19:02:09Z","timestamp":1736190129000},"page":"1211-1214","source":"Crossref","is-referenced-by-count":1,"title":["Double dose of dupilumab shows efficacy in treatment-resistant bullous pemphigoid"],"prefix":"10.1093","volume":"50","author":[{"given":"Kaitlyn","family":"Mills","sequence":"first","affiliation":[{"name":"Arizona State University, Biological Sciences , Phoenix, AZ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2732-6492","authenticated-orcid":false,"given":"Melody","family":"Maarouf","sequence":"additional","affiliation":[{"name":"US Dermatology Partners , Southwest Skin Specialists, Phoenix, AZ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2025052303165757700_llaf002-B1","article-title":"Bullous pemphigoid and other pemphigoid dermatoses","volume":"57","author":"Pratasava","year":"20211061","journal-title":"Medicina"},{"key":"2025052303165757700_llaf002-B2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"},{"key":"2025052303165757700_llaf002-B3","article-title":"Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: a case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"2025052303165757700_llaf002-B4","first-page":"e15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2023","journal-title":"Dermatol Ther"},{"key":"2025052303165757700_llaf002-B5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf002\/61356088\/llaf002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1211\/61356088\/llaf002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1211\/61356088\/llaf002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:17:06Z","timestamp":1747984626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/6\/1211\/7943553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":5,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf002","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,6]]}}}